High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety.
about
Antithrombin III for critically ill patientsAntithrombin III for critically ill patientsSurviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008A meta-analysis of controlled trials of recombinant human activated protein C therapy in patients with sepsis.PAMPs and DAMPs as triggers for DICContribution of protein Z and protein Z-dependent protease inhibitor in generalized Shwartzman reaction.A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsisA peptide of heparin cofactor II inhibits endotoxin-mediated shock and invasive Pseudomonas aeruginosa infection.The host response to sepsis and developmental impactThrombomodulin as an intravascular safeguard against inflammatory and thrombotic diseases.The Japanese guidelines for the management of sepsis.Efficacy of antithrombin in preclinical and clinical applications for sepsis-associated disseminated intravascular coagulation.Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis.Bench-to-bedside review: the role of glycosaminoglycans in respiratory disease.Analysis of the influence of antithrombin on microvascular thrombosis: anti-inflammation is crucial for anticoagulationClinical review: molecular mechanisms underlying the role of antithrombin in sepsis.The pathogenesis of sepsis.Antithrombin is protective against myocardial ischemia and reperfusion injury.Benefit profile of anticoagulant therapy in sepsis: a nationwide multicentre registry in JapanMutagenesis studies toward understanding the intracellular signaling mechanism of antithrombin.Severe sepsis and septic shock: management and performance improvement.Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding.Management of sepsis in neutropenic patients: guidelines from the infectious diseases working party of the German Society of Hematology and Oncology.Immunomodulatory therapy for sepsis: an update.Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO).Heparin protects against septic mortality via apoE-antagonism.Efficacy and Bleeding Risk of Antithrombin Supplementation in Patients With Septic Disseminated Intravascular Coagulation: A Third Survey.Observational study to compare antithrombin and thrombomodulin for disseminated intravascular coagulation.[Adjuvant treatment of sepsis: what is known?].A Proposal of the Modification of Japanese Society on Thrombosis and Hemostasis (JSTH) Disseminated Intravascular Coagulation (DIC) Diagnostic Criteria for Sepsis-Associated DIC.Recommendations for the use of antithrombin concentrates and prothrombin complex concentratesReduction of D-dimer levels after therapeutic administration of antithrombin in acquired antithrombin deficiency of severe sepsis.Coagulation deficiencies: a look to the future.All of the King's soldiers.Fluid resuscitation targeting sepsis-induced cardiovascular dysfunction: severity of disease as effect modifier.Antibodies against RAGE in sepsis and inflammation: implications for therapy.Evaluation of between-, within- and day-to-day variation of coagulation measured by rotational thrombelastometry (ROTEM).Antithrombin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study.Is Coagulopathy an Appropriate Therapeutic Target During Critical Illness Such as Trauma or Sepsis?Engineering D-helix of antithrombin in alpha-1-proteinase inhibitor confers antiinflammatory properties on the chimeric serpin.
P2860
Q24186159-2ED463BB-0FE4-485C-AA45-0F4127E0363AQ24242053-CCBC48C9-42F9-42B4-ACB0-C4784038F627Q24644984-49F1820B-6EEB-4B2C-83A4-DD57B20DB364Q24816510-2C461BFF-C83E-45FB-A484-FD685A6AC679Q27013790-8FCA10AA-6548-433A-B215-BB74A0ECEF69Q33409905-58D57A85-99A8-442B-B83D-E06A13CDA4E5Q33753012-1E686916-F5FF-4E29-8722-E169E4259481Q33927961-BDDFC2FE-6F7B-4F60-93AF-89CFFFBB0F43Q33950741-B0E1D5F4-42C7-46D7-9E31-2F5916B7121DQ34501341-7F8E26E7-5496-4B46-A28B-8C21AB357DD8Q35107094-45A44D74-880D-48D3-B0CE-120D62814D9AQ35107098-086AB21A-5CC2-4C4E-8822-89A2316F5EF2Q35201124-E4E9A086-DF1D-4B77-8981-5788FB18B96BQ35629808-B7905485-965A-44DC-B618-17E490B9E318Q35829030-64FC528C-0984-4B11-96FA-F798D04F7CC8Q36423261-B57ED45C-5A7C-4C6D-B7D2-9AB1D534F998Q36934401-039E4571-878A-4EFE-9F48-24DF6D0F575AQ36986076-7BAF5E59-D838-4615-A820-D151C8D0BC28Q37138741-99331869-0EC4-4540-8C05-9CC230B1B701Q37287790-CBECE59B-B923-42F8-B74F-253CCDA09105Q37562996-F573279F-C7C2-4324-A5AC-12C6E7138ADEQ37655890-8FA2ACA4-07FF-499B-AFA2-A415EBBC6DA6Q37805910-12313051-6463-4ED3-AD7F-CB08D7DB6433Q37949639-5CAA6D13-0FD1-4174-A653-EB21C790D438Q38207933-1B5ED5EE-544F-4AF1-BC74-1E54E40FDBEEQ38270791-086D6CC7-C038-4C29-B47E-AE50ECDA72A4Q39780897-31824B09-0DFD-4E81-B945-D2730913684AQ41595614-E9864509-7F8B-40D7-8C81-79DDD0323107Q41694620-99EE6AAC-9E0D-43A3-B59D-889B6021C05AQ41927869-57143588-D1E7-4A3F-BED3-E5427BA4C2D4Q42096335-854A550C-9D86-45B4-98C3-2161FCE57773Q43182531-BDAB183A-F0E5-4E8F-90CB-151C83F38017Q43517013-C8E3C029-FC6F-4E2D-AFEB-0352BA28B729Q46003363-BDA2E443-06D0-4138-9B3D-D801A0AF0AC2Q47151375-8B29189C-2188-4A80-B2B0-77E9F8E546B2Q47574722-52C28B50-1438-46CB-9282-D834F62712E3Q48108424-D953E424-53CE-4A7B-8F54-CCA858752934Q51076281-888EA574-60A0-4BC5-8B2E-B68EB3F0C86DQ51332285-B8AD8C70-E8B3-4894-9D6E-CD8EF6B36A8FQ53621386-A9701760-DCF6-46F5-9E33-2B6EBA0E1380
P2860
High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
High-dose antithrombin III in ...... of death: efficacy and safety.
@en
High-dose antithrombin III in ...... of death: efficacy and safety.
@nl
type
label
High-dose antithrombin III in ...... of death: efficacy and safety.
@en
High-dose antithrombin III in ...... of death: efficacy and safety.
@nl
prefLabel
High-dose antithrombin III in ...... of death: efficacy and safety.
@en
High-dose antithrombin III in ...... of death: efficacy and safety.
@nl
P2093
P1476
High-dose antithrombin III in ...... of death: efficacy and safety.
@en
P2093
Brian L Warren
Christian J Wiedermann
Heinz-Otto Keinecke
Helmut Ostermann
Joachim Kienast
Johannes N Hoffmann
Josef Briegel
KyberSept Investigators
Mathias Juers
Richard Strauss
P304
P356
10.1097/01.CCM.0000194731.08896.99
P407
P577
2006-02-01T00:00:00Z